Transfusion in HIV disease

Current Opinion in Hematology

Volumn 4, Issue 6, 1997, Pages 449-454

  Sloand, Elaine M ^a   Groopman, Jerome E ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; PROTEINASE INHIBITOR; ZIDOVUDINE;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; ERYTHEMA INFECTIOSUM; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LATENT VIRUS INFECTION; MYCOBACTERIUM INTRACELLULARE AVIUM; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTOPENIA; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 0030732255     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704060-00016     Document Type: Short Survey

References (63)

1. Saah AJ, Munoz A, Kuo V, Fox R, Kaslow RA, Phair JP, Rinaldo CR, Detels R, Polk BF, and the Multicenter AIDS Cohort Study (MACS): Predictors of the risk of development of acquired immunodeficiency syndrome within 24 months among gay men seropositive for human immunodeficiency virus type 1: a report from the Multicenter AIDS Cohort Study. Am J Epidemiol 1992, 135:1147-1155.
2. Spivak JL, Barnes DC, Fuchs E, Quinn TC: Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989, 261:3104-3107.
3. Markle HV: Cobalamin. Crit Rev Clin Lab Sci 1996, 33:247-356.
4. Boelaert JR, Weinberg GA, Weinberg ED: Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996, 5:36-46.
5. Naides SJ, Howard EJ, Swack NS, True CA, Stapleton JT: Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis 1993, 168:101-105.
6. Brown KE, Young NS: Parvovirus B19 Infection and hematopoiesis. Blood Rev 1995, 9:176-182.
7. Brown KE, Young NS: Parvovirus B19 in human disease. Annu Rev Med 1997, 48:59-67.
8. Kravcik S, Toye BW, Fyke K, Hawley-Foss N, Fillion D, Yurack JA, Cameron DW: Impact of Mycobacterium avium complex prophylaxis on the incidence of mycobacterial infections and transfusion-requiring anemia in an HIV-positive population. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:27-32.
9. Sloand EM, Klein HG, Banks SM, Vareldzis B, Merritt S, Pierce P: Epidemiology of thrombocytopenia in HIV infection. Eur J Haematol 1992, 48:168-172.
10. Brusamolino E, Malfitano A, Pagnucco G, Sacchi P, Orlandi E, Dornini G, Minoli L, Bemasconi C: HIV-related thrombocytopenic purpura: a study of 24 cases. Haematologica 1989, 74:51-56.
11. Bussel JB, Haimi JS: Isolated thrombocytopenia in patients infected with HIV: treatment with intravenous gammaglobulin. Am J Hematol 1988, 28:79-84.
12. Coyle TE: Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med Clin North Am 1997, 81:449-470.
13. Sloand E, Kumar P, Pierce PF: Chemotherapy for patients with pulmonary Kaposi's sarcoma: benefit of filgrastim (G-CSF) in supporting dose administration. South Med J 1993, 86:1219-1224.
14. Klaassen RJ, Mulder JW, Vlekke AB, Schattenkerk JK, Weigels HM, Lange JMA, von dem Borne AE: Autoantibodies against peripheral blood cells appear early in HIV infection and their prevalence increases with disease progression. Clin Exp Immunol 1990, 81:11-17.
15. Donahue RE, Johnson MM, Zon LI, Clark SC, Groopman JE: Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature 1987, 326:200-203.
16. +) hematopoietic progenitors in human immunodeficiency virus-1 seropositive thrombocytopenic individuals. Blood 1992, 79:2680-2687.
17. Louache F, Henri A, Betlaieb A, Oksenhendler E, Raguin G, Tulliez M, Vainchenker W: Role of human immunodeficiency virus replication in defective In vitro growth of hematopoietic progenitors. Blood 1992, 80:2991-2999.
18. Leiderman IZ, Greenberg ML, Adelsberg BR, Siegal FP: A glycoprotein inhibitor of in vitro granulopoiesis associated with AIDS. Blood 1987, 70:1267-1272.
19. Kaczmarski RS, Davison F, Blair E, Sutherland S, Moxham J, McManus T, Mufti GJ: Detection of HIV in haemopoietic progenitors. Br J Haematol 1992, 82:764-769.
20. Molina JM, Scadden DT, Sakaguchi M, Fuller B, Woon A, Groopman JE: Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. Blood 1990, 76:2476-2482. Provides data demonstrating the absence of HIV infection in progenitor cells in an HIV-infected population.
21. Folks TM, Kessler SW, Orenstein JM, Justement JS, Jaffe ES, Fauci AS: Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988, 242:919-922. Provides information contradictory to Molina et al. [20••] demonstrating that progenitor cells could be infected with HIV.
22. + progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 1995, 86:1749-1756. Provides information showing that at least in asymptomatic HIV-infected individuals progenitor cells are not a major reservoir of HIV infection.
23. + hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus. Blood 1990, 76:1281-1286.
24. De Luca A, Teofili L, Antinori A, lovino MS, Mencarini P, Bisconti E, Tamburrini E, Leone G, Ortona L: Haemopoietic CD34+ progenitor cells are not infected by HIV-1 in vivo but show impaired clonogenesis. Br J Haematol 1993, 85:20-24.
25. Kojouharoff G, Ottmann OG, von Briesen H, Geissler G, Rubsamen-Waigmann H, Hoelzer D, Ganser A: Infection of granulocyte/monocyte progenitor cells with HIV 1. Res Virol 1991, 142:151-157.
26. + bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 1992, 149:689-697.
27. Stutte HJ, Muller H, Falk S, Schmidts HL: Pathophysiological mechanisms of HIV-induced defects in haematopoiesis: pathology of bone marrow. Res Virol 1990, 141:195-200.
28. Sakaguchi M, Sato T, Groopman JE: Human immunodeficiency virus infection of megakaryocytic cells. Blood 1991, 77:481-485.
29. Schwartz GN, Kessler SW, Rothwell SW, Burrell LM, Reid TJ, Meltzer MS, Wright DG: Inhibitory effects of HIV-1-infected stromal cell layers on the production of myeloid progenitor cells in human long-term bone marrow cultures. Exp Hematol 1994, 22:1288-1296.
30. Scadden DT, Zeira M, Woon A, Wang Z, Schieve L, Ikeuchi K, Lim B, Groopman JE: Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood 1990, 76:317-322. Shows that marrow stromal cells and fibroblasts can be infected with HIV and could potentially provide a reservoir of infection.
31. Kunzi MS, Groopman JE: Identification of a novel human immunodeficiency virus strain cytopathic to megakaryocytic cells. Blood 1993, 81:3336-3342.
32. Marandin A, Canque B, Coulombel L, Gluckman JC, Vainchenker W, Louache F: In vitro infection of bone marrow-adherent cells by human immunodeficiency virus type 1 (HIV-1) does not alter their ability to support hematopoiesis. Virology 1995, 213:245-248.
33. Moses AV, Williams S, Heneveld ML, Strussenberg J, Rarick M, Loveless M, Bagby G, Nelson JA: Human immunodeficiency virus Infection of bone marrow endothellum reduces induction of stromal hematopoietic growth factors. Blood 1996, 87:919-925.
34. Sloand EM, Kumar P, Klein HG, Merritt S, Sacher R: Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994, 34:48-53. Although it was flawed in the sense that it was a retrospective study, it raised the question as to whether transfusion could be deleterious to HIV-infected individuals and provided for more controlled studies to further investigate this possibility.
35. Shepp DH, Moses JE, Kaplan MH: Seroepidemiology of cytomegalovirus in patients with advanced HIV disease: influence on disease expression and survival. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:460-468.
36. Havlik JA, Horsburgh CR, Metchock B, Williams PP, Fann SA, Thompson SE: Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992, 165:577-580.
37. Fuller A, Moaven L, Spelman D, Spicer WJ, Wraight H, Curtis D, Leydon J, Doultree J, Locarnini S: Parvovirus B19 in HIV infection: a treatable cause of anemia. Pathology 1996, 28:277-280.
38. Kerr JR: Parvovirus B19 infection. Eur J Clin Microbiol Infect Dis 1996, 15:10-29.
39. Brown KE, Young NS: Parvoviruses and bone marrow failure. Stem Cells 1996, 14:151-163.
40. Karpatkin S, Nardi MA, Hymes KB: Immunologic thrombocytopenic purpura after heterosexual transmission of human immunodeficiency virus (HIV). Ann Intern Med 1988, 109:190-193.
41. Savona S, Nardi MA, Lennette ET, Karpatkin S: Thrombocytopenic purpura in narcotics addicts. Ann Intern Med 1985, 102:737-741.
42. Jackson JB, Erice A, Englund JA, Edson JR, Balfour HH: Prevalence of cytomegalovirus antibody in hemophillacs and homosexuals infected with human immunodeficiency virus type 1. Transfusion 1988, 28:187-189.
43. Vamvakas E, Kaplan HS: Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993, 33:111-118.
44. Huang ES, Huong SM, Tegtmeier GE, Alford C: Cytomegalovirus: genetic variation of viral genomes. Ann N Y Acad Sci 1980, 354:332-346.
45. Glazer JP, Friedman HM, Grossman RA, Starr SE, Barker CF, Perloff LJ, Huang ES, Plotkin SA: Live cytomegalovirus vaccination of renal transplant candidates: a preliminary trial. Ann Intern Med 1979, 91:676-683.
46. Adler SP, McVoy MM: Cytomegalovirus infections in seropositive patients after transfusion: the effect of red cell storage and volume. Transfusion 1989, 29:667-671.
47. Thompson KS, Plapp FV, Long ND, Heenan TA: CMV infection in heart transplant recipients [abstract]. Transfusion 1992, 32(suppl 8S):65S.
48. Manez R, Kusne S, Martin M, Linden P, Irish W, Torre-Cisneros J, Kramer D, Ho M, Starzl TE: The impact of blood transfusion on the occurrence of pneumonitis in primary cytomegalovirus infection after liver transplantation. Transfusion 1993, 33:594-597.
49. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaju M, Haake R, Welk K, Fisher L, et al.: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant Blood 1995, 86:3598-3603.
50. Busch MP, Lee T-H, Heitman J: Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion suport of infected patients. Blood 1992, 80:2128-2135. This article provides in vitro evidence that exposure of HIV-infected lymphocytes to allogeneic lymphocytes may activate infection. This, in turn, provided the impetus for further studies on the effects of leukodepletion in this population.
51. Mudido PM, Georges D, Dorazio D, Yen-Lieberman B, Bae S, O'Brien WA, Spritzler J, Lederman MM: Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion 1996, 36:860-865. Provides in vivo evidence that transfusion may activate HIV.
52. Popovsky MA, Benson K, Glassman AB, Hume H, Oberman HA, Pisciotto PT, Anderson KC: Transfusion practices in human immunodeficiency virus-infected patients. Transfusion 1995, 35:612-616. Reviews the current transfusion practice in a series of blood banks nationwide.
53. Lee TH, Paglieroni T, Ohto H, Holland PV, Busch MP: Long-term multilineage chimerism of donor leukocytes in transfused trauma patients [abstract]. Blood 1996, 10(suppl 1):265a.
54. Yomtovian R, Kelly C, Bracey AW, McCraney SK, Renner SW, Williamson KR, Attar S: Procurement and transfusion of human immunodeficiency virus-positive or untested autologous blood units: issues and concerns: a report prepared by the Autologous Transfusion Committee of the American Association of Blood Banks. Transfusion 1995, 35:353-361.
55. Linden JV: Autologous blood errors and incidents [abstract]. Transfusion 1994, 34(suppl):28S.
56. Vanston V, Smith D, Eisenstaedt R: Should patients with human immunodeficiency virus infection or chronic hepatitis donate blood for autologous use? Transfusion 1995, 354:324-330.
57. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, Synold T, Relling MV, Ribeiro RC, Crist WM, Evans WE: Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997, 336:1781-1787.
58. Henry DH, Beall GN, Benson CA, Carey J, Cone LA, Eron LJ, Fiala M, Fischl MA, Gabin SJ, Gottlieb MS, et al.: Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med 1992, 117:739-748.
59. Glaspy JA, Chap L: The clinical application of recombinant erythropoietin in the HIV-infected patient Hematol Oncol Clin North Am 1994, 8:945-959.
60. Guo WX, Antakly T: AIDS-related Kaposi's sarcoma: evidence for direct stimulatory effect of glucocorticold on cell proliferation. Am J Pathol 1995, 146:727-734.
61. Ballem PJ, Belzberg A, Devine DV, Lyster D, Spruston B, Chambers H, Doubroff P, Mikulash K: Kinetic studies of the mechanisms of thrombocytopenia in patients with human Immunodeficiency virus infection. N Engl J Med 1992, 327:1779-1784.
62. Ellis ME, Neal KR, Leen CL, Newland AC: Alfa-2a recombinant interferon In HIV associated thrombocytopenia. BMJ 1987, 295:1519.
63. Morlat P, Dequae-Merchadou L, Dabis F, Chene G, Salamon R, Beylot J, the Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GESCA): Splenectomy and prognosis of HIV infection. AIDS 1996, 10:1170-1172.